Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to $2.7 million.

  • Abeona Therapeutics' Share-based Compensation rose 4905.76% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.2 million, marking a year-over-year increase of 6445.77%. This contributed to the annual value of $6.6 million for FY2024, which is 3901.01% up from last year.
  • Latest data reveals that Abeona Therapeutics reported Share-based Compensation of $2.7 million as of Q3 2025, which was up 4905.76% from $2.8 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Share-based Compensation peaked at $2.8 million during Q2 2025, and registered a low of $632000.0 during Q3 2022.
  • In the last 5 years, Abeona Therapeutics' Share-based Compensation had a median value of $1.6 million in 2023 and averaged $1.7 million.
  • In the last 5 years, Abeona Therapeutics' Share-based Compensation plummeted by 7508.87% in 2022 and then soared by 14636.08% in 2023.
  • Quarter analysis of 5 years shows Abeona Therapeutics' Share-based Compensation stood at $2.0 million in 2021, then crashed by 58.37% to $833000.0 in 2022, then soared by 81.75% to $1.5 million in 2023, then grew by 29.13% to $2.0 million in 2024, then soared by 37.54% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.8 million for Q2 2025, and $2.7 million during Q1 2025.